scout

Authors

Cynthia Yoshida, MD
Latest Article

UVA Screening Program Seeks to Get Ahead of Colorectal Cancer

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

Cyrus M. Khan, MD, of Allegheny Health Network
Cyrus M. Khan, MD

Cyrus M. Khan, MD, is an assistant professor of medicine at the Drexel University School of Medicine and assistant director of the Stem Cell Transplant Program at the Allegheny Health Network Cancer Institute in Pittsburgh, Pennsylvania.

Latest Article

Dr Khan on the Evolution of BTK Inhibitors in CLL

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

D. Ross Camidge, MD, University of Colorado Cancer Center
D. Ross Camidge, MD, University of Colorado School of Medicine
Dale Chenoweth
Latest Article

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Dale R. Shepard, MD, PhD, FACP, Taussig Cancer Institute, Cleveland Clinic
Dan Douer, MD, MKSCC
Dan Douer, MD, MSK
Dan Douer, MD, MSKÂ
Dan Douer, MD, MSKCC
Dan Duffy
Latest Article

Specialty Pharmacy: Build, Buy, or Partner

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dan Pollyea, MD, MS, University of Colorado Cancer Center
Dan Theodorescu, MD, PhD
Latest Article

Can New Technologies Be Used to Predict Treatment Response in Cancer Patients?

The next leap forward in cancer treatment will see physicians tailoring treatments based on patients' individualized tumor profiles.

Dana H. Felthouse, MBA
Latest Article

Mission Possible: Managing Specialty Pharmacy Costs and Utilization

To get the right drug in the right amount at the right time to the patient in the most cost-effective manner

Daniel A. Pollyea, MD, MS University of Colorado School of Medicine
Daniel Dosoretz MD
Latest Article

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Daniel E. Dosoretz, MD
Latest Article

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Daniel G. Haller, MD, FACP, FRCP, Perelman School of Medicine
Daniel G. Haller, MD,FACP,FRCP, University of Pennsylvania
Daniel G. Haller, MD, University of Pennsylvania
Daniel G. Stover, MD
Latest Article

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Daniel George, MD, Duke Cancer Institute
Daniel Heng,
Daniel HEng, MD, MPH, FRCPC, Tom Baker Cancer Center
Daniel Hier, MD, MBA
Latest Article

Everyone Loves e-Prescribing! Right?

Electronic prescribing is rapidly gaining support from a diverse array of healthcare organizations, government agencies, and technology corporations.

Daniel I. Quinn, MBBS, PhD, FRACP, FACP, University of Southern California
Daniel Indelicato MD
Latest Article

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Daniel J. George, MD, Duke
Daniel J. George, MD, Duke University Medical Center
Daniel P. Petrylak, MD, Yale